CoChat

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma

Zheng, Tongsen, Yin, Dalong, Lu, Zhaoyang, Wang, Jiabei, Li, Yuejin, Chen, Xi, Liang, Yingjian, Song, Xuan, Qi, Shuyi, Sun, Boshi, Xie, Changming, Meng, Xianzhi, Pan, Shangha, Liu, Jiaren, Jiang, Hongchi, Liu, Lianxin · 2014 · Molecular Cancer
Cited by 52

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Arsenic trioxide has been demonstrated as an effective anti-cancer drug against leukemia and solid tumors both in vitro and in vivo. However, recent phase II trials demonstrated that single agent arsenic trioxide was poorly effective against hepatocellular carcinoma (HCC), which might be due to drug resistance. METHODS: Mutation detection of p53 gene in arsenic trioxide resistant HCC cell lines was performed. The therapeutic effects of arsenic trioxide and Nutlin-3 on HCC were evaluated both in vitro and in vivo. A series of experiments including MTT, apoptosis assays, co-Immunoprecipitation, siRNA transfection, lentiviral infection, cell migration, invasion, and epithelial-mesenchy-mal transition (EMT) assays were performed to investigate the underlying mechanisms. RESULTS: The acquisition of p53 mutation contributed to arsenic trioxide resistance and enhanced metastatic potential of HCC cells. Mutant p53 (Mutp53) silence could re-sensitize HCC resistant cells to arsenic trioxide and inhibit the metastatic activities, while mutp53 overexpression showed the opposite effects. Neither arsenic trioxide nor Nutlin-3 could exhibit obvious effects against arsenic trioxide resistant HCC cells, while combination of them showed significant effects. Nutlin-3 can not only increase the intracellular arsenicals through inhibition of p-gp but also promote the p73 activation and mutp53 degradation mediated by arsenic trioxide. In vivo experiments indicated that Nutlin-3 can potentiate the antitumor activities of arsenic trioxide in an orthotopic hepatic tumor model and inhibit the metastasis to lung. CONCLUSIONS: Acquisitions of p53 mutations contributed to the resistance of HCC to arsenic trioxide. Nutlin-3 could overcome arsenic trioxide resistance and inhibit tumor metastasis through p73 activation and promoting mutant p53 degradation mediated by arsenic trioxide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-13-133

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 21

  1. Shao QS, Ye ZY, Ling ZQ, Ke JJ: Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide. World J Gastroenterol. 2005, 11 (22): 3451-3456. · doi:10.3748/wjg.v11.i22.3451
  2. Subbarayan PR, Lima M, Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol. 2007, 46 (4): 557-561. 10.1080/02841860601042456 · DOI
  3. Vahter M: Mechanisms of arsenic biotransformation. Toxicology. 2002, 181–182: 211-217. · DOI · Paper page
  4. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs. 2007, 25 (1): 77-84. · DOI
  5. Chen X, Zhang M, Liu LX: The overexpression of multidrug resistance-associated proteins and Gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep. 2009, 22 (1): 73-80. · doi:10.3892/or_00000410
  6. Schläwicke Engström K, Broberg K, Concha G, Nermell B, Warholm M, Vahter M: Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect. 2007, 115 (4): 599-605. 10.1289/ehp.9734 · DOI · Paper page
  7. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Lieberman MW: The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem. 2000, 275 (43): 33404-33408. 10.1074/jbc.M007030200 · DOI · Paper page
  8. Soussi T: p53 mutations and resistance to chemotherapy: a stab in the back for p73. Cancer Cell. 2003, 3 (4): 303-305. 10.1016/S1535-6108(03)00081-3 · DOI
  9. Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi-Balaei M, Abdolazimi Y, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH: Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010, 27 (3): 833-842. 10.1007/s12032-009-9294-9 · DOI
  10. Selivanova G, Ivaska J: Integrins and mutant p53 on the road to metastasis. Cell. 2009, 139 (7): 1220-1222. 10.1016/j.cell.2009.12.016 · DOI
  11. Muller PA, Vousden KH: p53 mutations in cancer. Nat Cell Biol. 2013, 15 (1): 2-8. · DOI · Paper page
  12. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004, 303 (5659): 844-848. 10.1126/science.1092472 · DOI · Paper page
  13. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, Cinatl J: Cinatl: reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist Nutlin-3. Cancer Res. 2009, 69 (2): 416-421. 10.1158/0008-5472.CAN-08-1856 · DOI · Paper page
  14. Secchiero P, Bosco R, Celeghini C, Zauli G: Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des. 2011, 17 (6): 569-577. 10.2174/138161211795222586 · DOI · Paper page
  15. Yan W, Zhang Y, Zhang J, Liu S, Cho SJ, Chen X: Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J Biol Chem. 2011, 286 (20): 17478-17486. 10.1074/jbc.M111.231639 · DOI · Paper page
  16. Yan W, Chen X, Zhang Y, Zhang J, Jung YS, Chen X: Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein. J Biol Chem. 2013, 288 (5): 2907-2913. 10.1074/jbc.M112.428607 · doi:10.1074/jbc.m112.428607
  17. Irwin MS: Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle. 2004, 3 (3): 319-323. · DOI · Paper page
  18. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P: The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica. 2012, 97 (11): 1722-1730. 10.3324/haematol.2012.062083 · DOI · Paper page
  19. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P: Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res. 2011, 17 (4): 762-770. 10.1158/1078-0432.CCR-10-2572 · DOI · Paper page
  20. Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT, Ding J: Growth arrest induced by C75, a fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther. 2006, 5 (8): 978-985. 10.4161/cbt.5.8.2883 · doi:10.4161/cbt.5.8.2883
  21. Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L: Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology. 2013, 12: 1847-1857. · DOI · Paper page

Cited by

See all 52

Metadata

Authors
Zheng, T., Yin, D., Lu, Z., Wang, J., Li, Y., Chen, X., Liang, Y., Song, X., Qi, S., Sun, B., Xie, C., Meng, X., Pan, S., Liu, J., Jiang, H., & Liu, L.
Venue
Molecular Cancer
Published
2014-05-31
Volume
13
Issue
1
ISSN
1476-4598
Cited by
52
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1186/1476-4598-13-133
The paper
Zheng, T., Yin, D., Lu, Z., Wang, J., Li, Y., Chen, X., Liang, Y., Song, X., Qi, S., Sun, B., Xie, C., Meng, X., Pan, S., Liu, J., Jiang, H., & Liu, L. (2014). Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. Molecular Cancer. https://doi.org/10.1186/1476-4598-13-133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.